Gene Editing

30 March -1 April 2020 | Business Design Centre London

 

 

2000+
Attendees
700+
1-2-1 Meetings
300+
Speakers
100+
Exhibitors
12
Streams

 

 

Gene Modified Cell Therapy

GENE MODIFIED CELL THERAPY, Tuesday 31 March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
09:20

Realizing the promise of ATMPs for patients around the world

  • Working with regulators to navigate scale up challenges in manufacturing
  • Strategies in supply chain and patient delivery
  • Tackling post manufacturing commercialization challenges such as pricing and finding highly skilled experts
  • Durability
10:20

Morning Coffee Break

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

11. Cord blood as a source of new cells
12. Tissue engineering for organ regeneration
Vaidehi Joshi

Vaidehi Joshi, Scientist II, Therapeutics, Organovo

13. TBC
14. Making allogeneic cell therapy a reality
Devyn Smith

Devyn Smith, Chief Operating Officer And Head Of Strategy, Sigilon

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

18. Ensuring ATMP access to patients
Delphine Roulland

Delphine Roulland, Director Government Affairs And Public Policy, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, B.O.K.U.

21. Neurological applications for ATMPs
22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

23. Renal applications for ATMPs
24. Tackling diabetes with ATMPs
3. TBC (Reserved for Schott)
Sebastian Kress

Sebastian Kress, Post Doc, BOKU

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

9. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

13:00

Lunch

Dr David Gilham
GENE MODIFIED CELL THERAPY
14:20

Broadening CAR-T’s horizons with NKG2G

  • New clinical data for non-gene edited allogenic CAR-T targeting NKG2D in solid tumour applications
  • Update on data for autologous CAR-T for AML
  • SHRNA platform preclinical update and IND status
GENE MODIFIED CELL THERAPY
14:40

Macrophages to tackle solid tumors: innate and adaptive immunity

Steven Lee
GENE MODIFIED CELL THERAPY
15:00

Using CAR T-cells to target the tumour vasculature

GENE MODIFIED CELL THERAPY
15:20

TBC Trilogy cells: a new approach to tackling solid tumours

Neill Moray Mackenzie
GENE MODIFIED CELL THERAPY
15:40

Taking Tumour infiltrating T cells into pivotal clinical studies

Cedrik Britten
GENE MODIFIED CELL THERAPY
16:00

TCR-Engineered T Cells for the Treatment of Solid Cancer: Maximising Scale and Benefit for NY-ESO TCR-T

16:20

Afternoon Break

Namir Hassan
GENE MODIFIED CELL THERAPY
17:00

A new TCR approach to take solid tumours

18:00

Close of Conference for the day - Please join us for an evening drinks reception at the iconic Emirates Stadium

last published: 28/Jan/20 14:05

GENE MODIFIED CELL THERAPY, Wednesday 1 April 2020

08:55

Opening Remarks

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
Adrian Woolfson
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

Dr Bob Valamehr
GENE MODIFIED CELL THERAPY
11:20

Creation of off-the-shelf TCR-less CAR T cell therapies

Ricardo Baptista
GENE MODIFIED CELL THERAPY
12:00

Automating and scaling manufacture of “off-the-shelf” engineered allogeneic CAR-T therapies

  • The presentation will highlight process steps that are a challenge to automate and scale.
  • Recent advances in developing our manufacturing process platform will be presented.
  • Analytical strategies to gain understanding and control of manufacturing process and product quality will be discussed.
Christina Coughlin
GENE MODIFIED CELL THERAPY
12:20

TBC Developing the next-suite of CAR-T using non-viral vectors and using CRISPR in the latest technologies

13:00

Neworking Lunch

David Pauza
GENE MODIFIED CELL THERAPY
14:20

ImmunoTox: Genetic manipulation of solid tumors to activate the natural γδ T cell response

Lawrence Lamb
GENE MODIFIED CELL THERAPY
14:40

Genetic engineering of drug-resistant gamma delta T cells for eradication of residual glioblastoma

  • Haploidentical gamma delta post-transplant immune “boost” and strategy for off the shelf therapy in glioblastoma trial
  • Drug Resistant Immunotherapy (DRI) - gamma delta T cells in combination with chemotherapy – allows superior targeting of residual glioblastoma.
  • Accrual and logistical information from ongoing trials.
Stewart Abbot
GENE MODIFIED CELL THERAPY
15:20

Gamma Delta T cells engineered with targeting moieties (CARs and TCRs) directed to cell surface and intracellular antigens

  • Development of engineered off-the-shelf allogeneic γδ T cell products
  • Preclinical efficacy and safety of chimeric antigen receptor-modified γδ T cell products
  • Large-scale cGMP-compliant manufacture of γδ T cell products
Jurgen Kuball
GENE MODIFIED CELL THERAPY
15:40

TEG’s as next generation of CAR

16:20

Networking refreshments

Conrad Russell Y Cruz
GENE MODIFIED CELL THERAPY
17:00

Engineering NK Cell Resistance to the Tumor Microenvironment

  • Role of TME-mediated immune suppression in tumor progression and its negative effects on NK cell function
  • Engineering NK cell resistance to TGF-beta
  • In vitro and in vivo function of gene modified NK cells
Stefanos Theoharis
GENE MODIFIED CELL THERAPY
17:20

Different approaches to allogeneic therapies

  • Allogeneic CAR approaches are being developed based on gene-edited T-cells, or different cell types, such as NK, NKT and gamma delta T-cells. Several of those are now in the clinic.
  • There are different technologies being used to generate these products, including for engineering, manufacturing and cell source.
  • This talk will offer a broad overview of the various efforts in the space and their key features.
Troels Jordansen
GENE MODIFIED CELL THERAPY
17:40

World’s first off-the-shelf NK cellular immunotherapy making cancer a chronic disease

  • How and why off-the-shelf?
  • Why are NK-cells important in cancer treatments?
  • Cancer management a viable option?
Mark Lowdell
GENE MODIFIED CELL THERAPY
18:00

Potentiation of the anti-tumour NK cell response in vitro and in vivo

Mark Lowdell
GENE MODIFIED CELL THERAPY
18:00

TBC: Potentiation of the NK Cell in response to myeloid leukaemia

last published: 28/Jan/20 14:05